Clinical Trials Browser

Phase 1/2 × Completed × alectinib × Clear all

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

Glioblastoma

NCT01801111 2018-11-02

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Phase 1/2 Completed

138 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung